US FDA device reviewers to use new worksheet from 1 May to capture benefit-risk determinations
This article was originally published in Clinica
Executive Summary
The US Food and Drug Administration has issued a final guidance document to explain how it considers the benefits and risks of medical devices reviewed under its pre-market approval (for high-risk products) and de novo (for low-risk products with no predicates) processes.